As a #Deeptech, our Technology Platform addresses key challenges in the industrialisation of loaded exosomes : 1) Consistency with a single-donor immortalized umbilical-cord derived cell line, 2) Scalability with our proprietary bioreactors enabling high yield production from small to industrial scale in a cost-effective way and 3) Efficient loading of therapeutic molecules (miRNA, proteins…)  with a unique microfluidic technology without altering the intrinsic properties of exosomes. 

 As a #Biotech, our exosomes possess inherent anti-inflammatory and regenerative properties, which we amplify by integrating miRNA to modulate key gene expression. This dual-action approach targets inflammation and promotes tissue regeneration—paving the way for a powerful, systemic intervention in inflammatory and degenerative diseases, with initial proof of concept in osteoarthritis. We’re also pursuing collaborations with biotech and pharma partners to expand our pipeline.